PMID- 19378696
OWN - NLM
STAT- MEDLINE
DCOM- 20090603
LR  - 20220409
IS  - 1121-189X (Print)
IS  - 1121-189X (Linking)
VI  - 18
IP  - 1
DP  - 2009 Jan-Mar
TI  - The global burden of mental disorders: an update from the WHO World Mental Health 
      (WMH) surveys.
PG  - 23-33
AB  - AIMS: The paper reviews recent findings from the WHO World Mental Health (WMH) 
      surveys on the global burden of mental disorders. METHODS: The WMH surveys are 
      representative community surveys in 28 countries throughout the world aimed at 
      providing information to mental health policy makers about the prevalence, 
      distribution, burden, and unmet need for treatment of common mental disorders. 
      RESULTS: The first 17 WMH surveys show that mental disorders are commonly 
      occurring in all participating countries. The inter-quartile range (IQR: 
      25th-75th percentiles) of lifetime DSM-IV disorder prevalence estimates 
      (combining anxiety, mood, externalizing, and substance use disorders) is 
      18.1-36.1%. The IQR of 12-month prevalence estimates is 9.8-19.1%. Prevalence 
      estimates of 12-month Serious Mental Illness (SMI) are 4-6.8% in half the 
      countries, 2.3-3.6% in one-fourth, and 0.8-1.9% in one-fourth. Many mental 
      disorders begin in childhood-adolescence and have significant adverse effects on 
      subsequent role transitions in the WMH data. Adult mental disorders are found to 
      be associated with such high role impairment in the WMH data that available 
      clinical interventions could have positive cost-effectiveness ratios. 
      CONCLUSIONS: Mental disorders are commonly occurring and often seriously 
      impairing in many countries throughout the world. Expansion of treatment could be 
      cost-effective from both employer and societal perspectives.
FAU - Kessler, Ronald C
AU  - Kessler RC
AD  - Department of Health Care Policy, Harvard Medical School, 180 Longwood Avenue, 
      Boston, MA 02115, USA. Kessler@hcp.med.harvard.edu
FAU - Aguilar-Gaxiola, Sergio
AU  - Aguilar-Gaxiola S
FAU - Alonso, Jordi
AU  - Alonso J
FAU - Chatterji, Somnath
AU  - Chatterji S
FAU - Lee, Sing
AU  - Lee S
FAU - Ormel, Johan
AU  - Ormel J
FAU - Ustun, T Bedirhan
AU  - Ustun TB
FAU - Wang, Philip S
AU  - Wang PS
LA  - eng
GR  - R01 DA016558/DA/NIDA NIH HHS/United States
GR  - R01 MH070884-05/MH/NIMH NIH HHS/United States
GR  - U01 MH060220-10/MH/NIMH NIH HHS/United States
GR  - R01 DA016558-06/DA/NIDA NIH HHS/United States
GR  - K05 DA015799/DA/NIDA NIH HHS/United States
GR  - U01 MH060220/MH/NIMH NIH HHS/United States
GR  - R01 MH070884/MH/NIMH NIH HHS/United States
GR  - U01MH060220/MH/NIMH NIH HHS/United States
GR  - R01 DA012058-05/DA/NIDA NIH HHS/United States
GR  - R01 DA012058/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - Italy
TA  - Epidemiol Psichiatr Soc
JT  - Epidemiologia e psichiatria sociale
JID - 9501447
SB  - IM
MH  - Cost of Illness
MH  - Data Collection
MH  - *Global Health
MH  - Humans
MH  - Mental Disorders/complications/*epidemiology
MH  - Prevalence
MH  - Severity of Illness Index
MH  - Time Factors
MH  - World Health Organization
PMC - PMC3039289
MID - NIHMS264248
COIS- Declaration of Interest: Professor Kessler has been a consultant for 
      GlaxoSmithKline Inc., Pfizer Inc., Wyeth-Ayerst, Sanofi-Aventis, Kaiser 
      Permanente, and Shire Pharmaceuticals; has served on advisory boards for Eli 
      Lilly & Company and Wyeth-Ayerst; and has had research support for his 
      epidemiological studies from Eli Lilly and Company, Pfizer Inc., Ortho-McNeil 
      Pharmaceuticals Inc., and Bristol-Myers Squibb.
EDAT- 2009/04/22 09:00
MHDA- 2009/06/06 09:00
PMCR- 2011/02/15
CRDT- 2009/04/22 09:00
PHST- 2009/04/22 09:00 [entrez]
PHST- 2009/04/22 09:00 [pubmed]
PHST- 2009/06/06 09:00 [medline]
PHST- 2011/02/15 00:00 [pmc-release]
AID - 10.1017/s1121189x00001421 [doi]
PST - ppublish
SO  - Epidemiol Psichiatr Soc. 2009 Jan-Mar;18(1):23-33. doi: 
      10.1017/s1121189x00001421.